Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several programmes on the discovery and development of vaccines and antibody therapeutics for several multidrug-resistant bacteria, primarily S. aureus as well as several viral diseases.

He has worked in the USA at the National Institutes of Health (NIH) and University of Virginia as a post-doctoral fellow and a Research Assistant Professor of pathology. He has also worked at the USA Army Medical Research Institute of Infectious Diseases (USAMRIID) as a Principal Investigator on the development of vaccines for bacterial toxins such as staphylococcal and B. anthracis toxins as well as viral haemorrhagic fever viruses such as Ebola and Marburg. In 2007, he founded IBT to translate his research findings into practical solutions for emerging infectious diseases. He developed several large programmes primarily funded by US government grants totalling over $80M.  His team has developed the first multicomponent, entirely toxoid-based vaccine candidate for S. aureus called IBT-V02.  IBT-V02 is currently nearing clinical evaluation under support from CARB-X and Novo REPAIR Impact Fund.

Javad has published over 120 peer-reviewed publications ranging from basic research in haematology, signal transduction, as well as vaccine and antibody discovery for infectious diseases.

Javad completed the school of Pharmacy at the University of Frankfurt in 1990 and went on to complete his PhD in molecular immunology at Johannes Wolfgang University in Mainz, Germany from 1990-1994.